104 related articles for article (PubMed ID: 32132043)
1. Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.
Vidal AC; Duong F; Howard LE; Wiggins E; Freedland SJ; Bhowmick NA; Gong J
Anticancer Res; 2020 Mar; 40(3):1459-1462. PubMed ID: 32132043
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD105 is prognostic of disease recurrence in prostate cancer patients.
Placencio-Hickok VR; Madhav A; Kim S; Duong F; Angara B; Liu Z; Bhowmick NA
Endocr Relat Cancer; 2020 Jan; 27(1):1-9. PubMed ID: 31648185
[TBL] [Abstract][Full Text] [Related]
3. Differential levels of soluble endoglin (CD105) in myeloid malignancies.
Calabrò L; Fonsatti E; Bellomo G; Alonci A; Colizzi F; Sigalotti L; Altomonte M; Musolino C; Maio M
J Cell Physiol; 2003 Feb; 194(2):171-5. PubMed ID: 12494455
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
5. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.
Tsirakis G; Pappa CA; Spanoudakis M; Chochlakis D; Alegakis A; Psarakis FE; Stratinaki M; Stathopoulos EN; Alexandrakis MG
Eur J Intern Med; 2012 Jun; 23(4):368-73. PubMed ID: 22560388
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome is associated with aggressive prostate cancer regardless of race.
Guerrios-Rivera L; Howard LE; Wiggins EK; Hoyo C; Grant DJ; Erickson TR; Ithisuphalap J; Freedland AR; Vidal AC; Fowke JH; Freedland SJ
Cancer Causes Control; 2023 Mar; 34(3):213-221. PubMed ID: 36450931
[TBL] [Abstract][Full Text] [Related]
8. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
9. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
10. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
Jamnagerwalla J; Howard LE; Allott EH; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freeman MR; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):252-259. PubMed ID: 29282360
[TBL] [Abstract][Full Text] [Related]
11. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
12. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
[TBL] [Abstract][Full Text] [Related]
13. Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.
Guerrios-Rivera L; Howard L; Frank J; De Hoedt A; Beverly D; Grant DJ; Hoyo C; Freedland SJ
Urology; 2017 Jul; 105():129-135. PubMed ID: 28408337
[TBL] [Abstract][Full Text] [Related]
14. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.
Josefsson A; Wikström P; Granfors T; Egevad L; Karlberg L; Stattin P; Bergh A
Eur Urol; 2005 Oct; 48(4):577-83. PubMed ID: 15990221
[TBL] [Abstract][Full Text] [Related]
15. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
Diolombi ML; Epstein JI
BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
17. Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project.
Allott EH; Arab L; Su LJ; Farnan L; Fontham ET; Mohler JL; Bensen JT; Steck SE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):48-54. PubMed ID: 27595916
[TBL] [Abstract][Full Text] [Related]
18. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
19. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
20. Gleason score 5 + 3 = 8 (grade group 4) prostate cancer-a rare occurrence with contemporary grading.
Kryvenko ON; Williamson SR; Schwartz LE; Epstein JI
Hum Pathol; 2020 Mar; 97():40-51. PubMed ID: 31923450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
